PBL Gains Approval to Advance Next Generation Anthrax Vaccine
Porton Biopharma Ltd (PBL) has announced that it has signed a modification to its contract with the US National Institute of Health's National Institute of Allergy and Infectious Diseases (NIAID) to advance a next generation intra-nasal anthrax vacci … (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - June 19, 2017 Category: Pharmaceuticals Source Type: news
BioThrax (Anthrax Vaccine Adsorbed Emergent BioSolutions) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 5, 2017 Category: Drugs & Pharmacology Source Type: news
Emergent signs $100m BARDA contract to deliver BioThrax
US-based Emergent BioSolutions has signed a $100m contract with the Biomedical Advanced Research and Development Authority (BARDA) to deliver BioThrax (Anthrax Vaccine Adsorbed) to the Strategic National Stockpile (SNS). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - March 21, 2017 Category: Pharmaceuticals Source Type: news
Emergent BioSolutions gets $100 million anthrax contract from feds
Gaithersburg-based Emergent BioSolutions Inc. won another lucrative anthrax contract from the feds, this time totaling $100 million over two years.
Emergent (NYSE: EBS) received the contract through the Biomedical Advanced Research and Development Authority to add more of its anthrax vaccine, BioThrax, to the country's national stockpile. The company first announced the planned purchase in December, along with another Centers for Disease Cont rol and Prevention contract worth up to $911 million for… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - March 20, 2017 Category: Pharmaceuticals Authors: Tina Reed Source Type: news
Meet Anne Schuchat, The Pro-Vaccine Researcher Who Just Took Over The CDC
This reporting is brought to you by HuffPost’s health and science platform, The Scope. Like us on Facebook and Twitter and tell us your story: scopestories@huffingtonpost.com.
function onPlayerReadyVidible(e){'undefined'!=typeof HPTrack&&HPTrack.Vid.Vidible_track(e)}!function(e,i){if(e.vdb_Player){if('object'==typeof commercial_video){var a='',o='m.fwsitesection='+commercial_video.site_and_category;if(a+=o,commercial_video['package']){var c='&m.fwkeyvalues=sponsorship%3D'+commercial_video['package'];a+=c}e.setAttribute('vdb_params',a)}i(e.vdb_Player)}else{var t=arguments.callee;setTi...
Source: Healthy Living - The Huffington Post - January 24, 2017 Category: Consumer Health News Source Type: news
Porton Biopharma (PBL) Brochure
Porton Biopharma (PBL) manufactures the UK's licensed anthrax vaccine for and on behalf of the UK Government. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - January 19, 2017 Category: Pharmaceuticals Source Type: news
Our news predictions for 2017
Climate change continues to impact on public health
Despite what many commenters have said in 2016, climate change is real and is ongoing. That's the thing about science. Just because you don't believe in it, it doesn't go away.
In 2016 we have seen evidence of the impact of climate change in a number of different ways.
There was an anthrax outbreak in northern Russia as warm weather caused the release of previously frozen deadly anthrax spores.
And many experts think that the spread of the Zika virus across much of the Americas was made possible, in part, by changes in temperature that created environments in which the ...
Source: NHS News Feed - December 30, 2016 Category: Consumer Health News Tags: QA articles Special reports Source Type: news
Why stock in this Gaithersburg biotech is up more than 25 percent
The share price of Gaithersburg-based Emergent BioSolutions Inc. remains up more than 25 percent this week after announcing Dec. 8 it scored federal deals worth up to $1 billion to supply the Strategic National Stockpile for millions of doses of its anthrax vaccine.
Emergent (NYSE: EBS) was awarded the contract with the Centers for Disease Control worth up to $911 million for 29.4 million doses of BioThrax through 2021. The company also received a separate notice that the Biomedical Advanced Research… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - December 13, 2016 Category: American Health Authors: Tina Reed Source Type: news
Why stock in this Gaithersburg biotech is up more than 25 percent
The share price of Gaithersburg-based Emergent BioSolutions Inc. remains up more than 25 percent this week after announcing Dec. 8 it scored federal deals worth up to $1 billion to supply the Strategic National Stockpile for millions of doses of its anthrax vaccine.
Emergent (NYSE: EBS) was awarded the contract with the Centers for Disease Control worth up to $911 million for 29.4 million doses of BioThrax through 2021. The company also received a separate notice that the Biomedical Advanced Research… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 13, 2016 Category: Biotechnology Authors: Tina Reed Source Type: news
HHS supports next-generation anthrax vaccine into advanced development
ASPR ' s BARDA is contracting with Emergent BioSolutions to work towards licensing an anthrax vaccine with the FDA. (Source: PHPartners.org)
Source: PHPartners.org - September 30, 2016 Category: Global & Universal Source Type: news
Altimmune nabs $120.2 million federal contract for nasal spray anthrax vaccine
Gaithersburg-based Altimmune Inc. was awarded a five-year federal contract worth up to $120.2 million for the development of its nasal spray anthrax vaccine candidate.
Under the contract from the U.S. Biomedical Advanced Research and Development Authority, or BARDA, Altimmune was awarded $14.3 million to fund its Phase 1 trial for the vaccine candidate NasoShield. The contract also includes options to receive up to an additional $105.9 million to fund further pr eclinical, clinical and manufacturing… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - August 10, 2016 Category: Biotechnology Authors: Tina Reed Source Type: news
Altimmune nabs $120.2 million federal contract for nasal spray anthrax vaccine
Gaithersburg-based Altimmune Inc. was awarded a five-year federal contract worth up to $120.2 million for the development of its nasal spray anthrax vaccine candidate.
Under the contract from the U.S. Biomedical Advanced Research and Development Authority, or BARDA, Altimmune was awarded $14.3 million to fund its Phase 1 trial for the vaccine candidate NasoShield. The contract also includes options to receive up to an additional $105.9 million to fund further pr eclinical, clinical and manufacturing… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 10, 2016 Category: Pharmaceuticals Authors: Tina Reed Source Type: news
Pfenex reports positive Phase Ia Px563L anthrax vaccine study results
US-based, clinical-stage biotechnology company Pfenex has reported a positive outcome from its Phase Ia Px563L anthrax vaccine study. (Source: Drug Development Technology)
Source: Drug Development Technology - August 8, 2016 Category: Pharmaceuticals Source Type: news
PharmAthene Inc.: Government giving Emergent BioSolutions unfair advantage in anthrax contracting
Annapolis-based biodefense company PharmAthene Inc. filed a complaint against the Department of Health and Human Services, claiming it is giving a de facto sole-source anthrax contract to competitor Emergent BioSolutions Inc. with its latest solicitation.
In a protest filed with the U.S. Government Accountability Office, officials from PharmAthene said the solicitation was written in a way that eliminated competition and ensured that an award for a next-generation anthrax vaccine would go to Gaithersburg-based… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 5, 2016 Category: Pharmaceuticals Authors: Tina Reed Source Type: news
PharmAthene Inc.: Government giving Emergent BioSolutions unfair advantage in anthrax contracting
Annapolis-based biodefense company PharmAthene Inc. filed a complaint against the Department of Health and Human Services, claiming it is giving a de facto sole-source anthrax contract to competitor Emergent BioSolutions Inc. with its latest solicitation.
In a protest filed with the U.S. Government Accountability Office, officials from PharmAthene said the solicitation was written in a way that eliminated competition and ensured that an award for a next-generation anthrax vaccine would go to Gaithersburg-based… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - August 5, 2016 Category: Biotechnology Authors: Tina Reed Source Type: news
